MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 05-16-2026
Horizon Therapeutics Public Limited Company Cash Conversion Cycle 2011-2026 | HZNP
Annual Cash Conversion Cycle Horizon Therapeutics Public Limited Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107 | 127 | 113 | 149 | 154 | 178 | 154 | 79.3 | 54.6 | 36.9 | 23.3 | -274 | 44.2 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 178 | -274 | 72.7 |
Quarterly Cash Conversion Cycle Horizon Therapeutics Public Limited Company
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 101 | 93.6 | - | 62.7 | 67.2 | 143 | - | 138 | 156 | 253 | 80.8 | 117 | 158 | 170 | 103 | 144 | 149 | 169 | 138 | 151 | 160 | 197 | 152 | 156 | 147 | 196 | 89.9 | 134 | 108 | 115 | 78.5 | 84.8 | 111 | 115 | 65 | 89.8 | 102 | 79 | 48.4 | 60.4 | 131 | 102 | 49.7 | 50 | 82.3 | 106 | 61.4 | 793 | 162 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 793 | 48.4 | 132 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
3.11 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Happiness Biotech Group Limited
HAPP
|
-3.12 K | - | 1.35 % | $ 17.8 M |  China |
 |
Coherus BioSciences
CHRS
|
149 | $ 1.45 | -7.94 % | $ 170 M |  USA |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M | China |
 |
Deciphera Pharmaceuticals
DCPH
|
-101 | - | - | $ 2.18 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Compugen Ltd.
CGEN
|
-82.7 | $ 2.1 | -5.41 % | $ 196 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
1.73 | - | - | $ 2.17 B | USA |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | Britain |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 51.84 | -8.97 % | $ 4.66 B |  Schweiz |
 |
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M |  Germany |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Celyad Oncology SA
CYAD
|
-55.7 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | USA |
 |
Celldex Therapeutics
CLDX
|
-3.74 K | $ 28.62 | -4.38 % | $ 1.9 B | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-1.6 K | - | -4.36 % | $ 27 M | USA |
 |
Anika Therapeutics
ANIK
|
192 | $ 14.48 | -2.1 % | $ 208 M | USA |
 |
Advaxis
ADXS
|
-82.3 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 21.23 | -3.28 % | $ 2.7 B | USA |